Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the clinical efficacy and safety of tralokinumab as
compared to placebo. Investigational product will be administered as subcutaneous injection.
All patients will continue background therapy for ulcerative colitis as per local standards
of care in addition to investigational product.